Trastuzumab Biosimilar Yields Similar Response Rates in HER2-Positive Breast Cancer

A biosimilar yielded equivalent response rates to trastuzumab at 24 weeks in a study of women with HER2-positive metastatic breast cancer.

Source: CancerNetwork - December 6, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news